T. Rowe Price Associates’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

T. Rowe Price Associates’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-730,864	Closed	-$7.29M	–	3038
2021 Q4	$7.29M	Hold	730,864	–	–	﹤0.01%	1455
2021 Q3	$7.28M	Hold	730,864	–	–	﹤0.01%	1466
2021 Q2	$7.45M	Sell	730,864 -56,026	-7%	-$562K	﹤0.01%	1452
2021 Q1	$7.94M	Buy	786,890 +20,300	+3%	+$216K	﹤0.01%	1424
2020 Q4	$8.17M	Buy	+766,590	New	+$7.79M	﹤0.01%	1376

Other funds holding EUCRU

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.72% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

T. Rowe Price Associates's EUCRU Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2022, closing a stake of 730,864 shares — an estimated $7.29M sold.

T. Rowe Price Associates first reported a position in EUCRU in Q4 2020 and held it in 5 quarters. The position peaked at $8.17M in Q4 2020. 19 funds tracked by Wall St. Rank hold EUCRU as of Q1 2022.

T. Rowe Price Associates reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
T. Rowe Price Associates sold 730,864 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2022, an estimated $7.29M.
T. Rowe Price Associates first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 5 quarters.
T. Rowe Price Associates's Eucrates Biomedical Acquisition Corp. Unit position peaked at $8.17M in Q4 2020.
19 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.